Skip to main content
Premium Trial:

Request an Annual Quote

We Get in Your Face

Premium

I congratulate you for the excellent job of publishing an informative and accurate article on genomics grids (“Getting to Genomics ‘Grid Nirvana,’” April 2003). In an area filled with hyperbole and marketing sales pitches, you struck a reasonable balance in illustrating the visionary, unrealized aspects of grid technology when contrasted with the reality of the uses to which grids are currently being used for the processing of genomic information. I feel that the article will genuinely help both the technical and non-technical person to understand the issues associated with the utilization of grid technology.

It is clear that your organization invested a large amount of time and resources in researching, writing, and producing such a well-rounded article.

I risked being very open with Aaron Sender and I am pleased that you folks dealt fairly with the topic matter. Please, feel free to contact me in the future on this or other topic areas.

Doug Brown, Center for Integrated Fungal Research, NC State University

 

I wanted to congratulate you on a great article on grid computing. I am happy for how it turned out, and to have been some help to you in it.

Thanks again for the great article, and for your continued interest!

Ernest F. Retzel, Director, Center for Computational Genomics and Bioinformatics, University of Minnesota

 

Nat Goodman’s article “Microarrays: Hazardous to Your Science,” April 2003, is excellent food for thought.

I must say I am impressed with [your] publication, as one of my colleagues gave me his copy this morning. The style is refreshing. GT seems to “get in the face” of science in that there is as much myth as fact in data generated by “technologists.” Or to put it another way: “it’s about time one calls a spade a spade.” Good work. I am a firm believer that controversy or healthy, objective discussion of the issues is fuel for innovation and scientific improvement.

Keep up the good work.

Mike Crawford, High Throughput Genomics

I find it astounding that you would publish an interview with Andrew Carr, president of Amersham Biosciences (“Carr Goes for Fuel Efficiency,” March 2003), in which he touts the very technology that he and his managers gutted a few weeks before — namely, DNA sequencing/genomics. Carr is now left to manage a very weakened portfolio of discovery products with nothing in the pipeline. This is more like “running on empty” than “fuel efficiency.”

Parke Flick, PhD

 

Editor’s note:

GT’s press deadline is one month in advance of the print date; the March issue went to the printer on February 7. Amersham announced its reorganization on February 27. Considering that Carr agreed to spend an hour in his office with GT on January 23 and gave no hint at that time of any impending organizational changes, our impression is that he was as blindsided by the reorganization as we were.

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.